Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 14/20 | 0.60 |
| ▸ | UGT1A4 | P22310 | 1/20 | 0.60 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | STS | P08842 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12780413 | 0.89 | CYP19A1 (0.50) | CYP19A1UGT1A4PDE4DTP53L3MBTL1 | |
| SCHEMBL2350295 | 0.81 | CYP19A1 (0.58) | CYP19A1UGT1A4PDE4DCYP11B1CYP11B2 | |
| Anastrozole SCHEMBL177942 | 0.75 | CYP19A1 (1.00) | CYP19A1UGT1A4PDE4DESR1STS | |
| Anastrozole SCHEMBL27927481 | 0.75 | CYP19A1 (1.00) | CYP19A1UGT1A4PDE4DESR1STS | |
| SCHEMBL5955314 | 0.75 | CYP19A1 (0.58) | CYP19A1UGT1A4PDE4DESR1STS | |
| Anastrozole SCHEMBL9726 | 0.75 | CYP19A1 (1.00) | CYP19A1UGT1A4PDE4DESR1STS | |
| Anastrozole SCHEMBL3172308 | 0.74 | CYP19A1 (0.97) | CYP19A1UGT1A4PDE4DESR1STS | |
| Anastrozole SCHEMBL5917785 | 0.74 | CYP19A1 (0.97) | CYP19A1UGT1A4PDE4DESR1STS | |
| SCHEMBL13530998 | 0.74 | CYP19A1 (0.60) | CYP19A1UGT1A4PDE4DESR1STS | |
| Anastrozole SCHEMBL28771766 | 0.74 | CYP19A1 (0.97) | CYP19A1UGT1A4PDE4DESR1STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060189670-A1 | Process for the preparation of anastrozole and intermediates thereof | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2006-08-24 | — | — | US | claimed |
| EP-2456758-B1 | A PROCESS FOR PREPARING TRISUBSTITUTED PHENYL DERIVATIVES COMPRISING A (1H-1,2,4-TRIAZOL-1-YL)ALKYL GROUP | HEXAL AG (DE) | 2014-08-06 | — | — | EP | disclosed |
| CN-102050796-B | Method for preparing alpha,alpha,alpha',alpha'-tetramethyl-5-(1H-1,3,4-triazole-1-ylmethyl)-1,3-phenylenediacetonitrile | CHANGZHOU NO 4 PHARMACEUTICAL FACTORY CO LTD | 2012-09-26 | — | — | CN | disclosed |
| CN-102050796-B | Method for preparing alpha,alpha,alpha',alpha'-tetramethyl-5-(1H-1,3,4-triazole-1-ylmethyl)-1,3-phenylenediacetonitrile | CHANGZHOU NO 4 PHARMACEUTICAL FACTORY CO LTD | 2012-09-26 | — | — | CN | disclosed |
| WO-2011083079-A1 | A PROCESS FOR PREPARING TRISUBSTITUTED PHENYL DERIVATIVES COMPRISING A (1H-1,2,4-TRIAZOL-1-YL)ALKYL GROUP | HEXAL AKTIENGESELLSCHAFT (DE) | 2011-07-14 | — | — | WO | disclosed |
| EP-2343278-A1 | A process for preparing trisubstituted phenyl derivatives comprising a (1H-1,2,4-triazol-1-yl)alkyl group | Hexal AG (DE) | 2011-07-13 | — | — | EP | disclosed |
| CN-102050796-A | Method for preparing alpha,alpha,alpha',alpha'-tetramethyl-5-(1H-1,3,4-triazole-1-ylmethyl)-1,3-phenylenediacetonitrile | CHANGZHOU NO 4 PHARMACEUTICAL FACTORY LTD | 2011-05-11 | — | — | CN | disclosed |
| CN-102050796-A | Method for preparing alpha,alpha,alpha',alpha'-tetramethyl-5-(1H-1,3,4-triazole-1-ylmethyl)-1,3-phenylenediacetonitrile | CHANGZHOU NO 4 PHARMACEUTICAL FACTORY LTD | 2011-05-11 | — | — | CN | disclosed |
| US-20110065927-A1 | PROCESS FOR PREPARING PURE ANASTROZOLE | CADILA HEALTHCARE LIMITED (IN) | 2011-03-17 | — | — | US | disclosed |
| US-20100099888-A1 | Process for the preparation of anticancer drugs | VILLA MARCO | 2010-04-22 | — | — | US | disclosed |
| US-20080177081-A1 | Process for Preparation of Anastrozole | FORMOSA LABORATORIES, INC. (TW) | 2008-07-24 | — | — | US | disclosed |
| US-20080177081-A1 | Process for Preparation of Anastrozole | FORMOSA LABORATORIES, INC. (TW) | 2008-07-24 | — | — | US | disclosed |
| US-20080177081-A1 | Process for Preparation of Anastrozole | FORMOSA LABORATORIES, INC. (TW) | 2008-07-24 | — | — | US | disclosed |
| US-20080076933-A1 | PROCESS FOR MAKING ANASTROZOLE | SYNTHON BV (NL) | 2008-03-27 | — | — | US | disclosed |
| WO-2007134846-A2 | PROCESS FOR PURIFICATION OF ANASTROZOLE | SYNTHON B.V. (NL) | 2007-11-29 | — | — | WO | disclosed |
| US-20070100148-A1 | PROCESS FOR PREPARING ANASTROZOLE | DR. REDDY'S LABORATORIES, INC. | 2007-05-03 | — | — | US | disclosed |
| WO-2007039913-A1 | PROCESS FOR THE PREPARATION OF 2,2’-[5-(1,2,4-TRIAZOLE-1-YLMETHYL) -1,3-PHENYLENE] DI (2-METHYLPROPIONITRILE). | USV LIMITED (IN) | 2007-04-12 | — | — | WO | disclosed |
| US-20060189670-A1 | Process for the preparation of anastrozole and intermediates thereof | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2006-08-24 | — | — | US | disclosed |
| EP-0296749-B1 | (Substituted aralkyl) heterocyclic compounds | ZENECA LTD (GB) | 1994-10-26 | — | — | EP | disclosed |
| US-4935437-A | (Substituted aralkyl) heterocyclic compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070100148-A1 | PROCESS FOR PREPARING ANASTROZOLE | CYP19A1, CYP2C19, CYP3A7 | CYP19A1 1/4885UGT1A4 76/4885PDE4D 1014/4885 |
| US-20080177081-A1 | Process for Preparation of Anastrozole | CYP19A1, CYP3A5, CYP2C19 | CYP19A1 1/4885UGT1A4 56/4885PDE4D 249/4885 |
| US-20060189670-A1 | Process for the preparation of anastrozole and intermediates thereof | CYP19A1, CYP1B1, CYP4B1 | CYP19A1 1/4885UGT1A4 191/4885PDE4D 1357/4885 |
| US-20080076933-A1 | PROCESS FOR MAKING ANASTROZOLE | CYP19A1, CYP3A4, CYP2C19 | CYP19A1 1/4885UGT1A4 47/4885PDE4D 1598/4885 |
| US-20110065927-A1 | PROCESS FOR PREPARING PURE ANASTROZOLE | CYP19A1, NR5A1, ESR1 | CYP19A1 1/4885UGT1A4 270/4885PDE4D 299/4885 |
| US-20100099888-A1 | Process for the preparation of anticancer drugs | CYP19A1, NME1, NME2 | CYP19A1 1/4885UGT1A4 2162/4885PDE4D 1322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.